PYC Therapeutics (ASX:PYC) Advances PMS Drug Candidate to Clinical Trials
PYC Therapeutics (ASX:PYC) advances its PMS drug candidate, PYC-002, with promising data supporting its progression to clinical trials.
PYC Therapeutics (ASX:PYC) advances its PMS drug candidate, PYC-002, with promising data supporting its progression to clinical trials.
North Stawell Minerals (ASX:NSM) announces a $3.6M capital raise to fund exploration initiatives at Darlington and Wildwood projects.
Duxton Farms (ASX:DBF) announces a strategic merger to expand its agricultural portfolio and declares an 85% special dividend.
Percheron Therapeutics (ASX:PER) secures exclusive worldwide license for HMBD-002, advancing its oncology drug pipeline and future clinical trials.
Aurizon Holdings Limited (ASX:AZJ) anticipates FY2025 EBITDA of $1.575b and announces a leadership restructuring to enhance operational synergy.
Yowie Group Ltd (ASX:YOW) faces interim orders restraining its takeover bid for Keybridge Capital Limited, impacting the acquisition process.
Manuka Resources (ASX:MKR) announces financing discussions and updates its silver & gold production strategy for the Cobar Basin.
Patriot Battery Metals (ASX:PMT) launches work programs to develop tantalum as a high-value by-product at its Shaakichiuwaanaan project.
MIXI Australia recommends an all-cash takeover offer of $1.20 per share for PointsBet Holdings Limited (ASX:PBH).
Everest Metals (ASX:EMC) confirms a continuous gold trend through extensive drilling at Revere Project, advancing towards maiden JORC Mineral Resource Estimate.